-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275

Benzinga·07/23/2026 18:05:51
Listen to the news
Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $256 to $275.